FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1Preeti Narayan, Julia A. Beaver, Jiang Liu et al.|Clinical Cancer Research|2020Cited by 185
FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast CancerSuparna Wedam, Julia A. Beaver, Lola A. Fashoyin‐Aje et al.|Clinical Cancer Research|2020Cited by 92
FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast CancerLynn Howie, Julia A. Beaver, Nancy S. Scher et al.|Clinical Cancer Research|2018Cited by 68
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trialsJaleh Fallah, Harpreet Singh, Lijun Zhang et al.|The Lancet Oncology|2021Cited by 15